Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States

Background: The US Food and Drug Administration has recently approved abaloparatide (ABL) for treatment of women with postmenopausal osteoporosis (PMO) at high risk of fracture. With increasing health care spending and drug prices, it is important to quantify the value of newly available treatment o...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Pharmacother
Main Authors: Le, Quang A., Hay, Joel W., Becker, Russell, Wang, Yamei
Formato: Artigo
Idioma:Inglês
Publicado em: SAGE Publications 2018
Assuntos:
Research Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6311620/
https://ncbi.nlm.nih.gov/pubmed/30160186
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1060028018798034
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados